InsiderSignal.AI

InsiderSignal.ai

CSTL - Castle Biosciences Inc

Insider Sale by Maetzold Derek J (Pres, Chief Exec. Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Maetzold Derek J, serving as Pres, Chief Exec. Officer at Castle Biosciences Inc (CSTL), sold 4,172 shares at $25.55 per share, for a total transaction value of $106,599.00. Following this transaction, Maetzold Derek J now holds 275,593 shares of CSTL.

This sale represents a 1.00% decrease in Maetzold Derek J's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, March 26, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 30, 2026, 4 days after the trade was made.

Castle Biosciences Inc operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Maetzold Derek J

Pres, Chief Exec. Officer

Derek J. Maetzold is the Founder, President, Chief Executive Officer, and Board Member of Castle Biosciences Inc. (CSTL), a molecular diagnostics company focused on personalized testing for cancers like skin cancer.[[1]](https://convention.bio.org/speaker/derek-maetzold)[[2]](https://txlifescienceforum.org/person/derek-maetzold) He founded the company in 2007, launching operations in late 2008 with co-founders Toby Juvenal and Kristen Oelschlager, driven by the vision to enhance cancer treatment plans through genomic information alongside traditional clinical factors.[[1]](https://convention.bio.org/speaker/derek-maetzold)[[2]](https://txlifescienceforum.org/person/derek-maetzold)[[4]](https://career.egr.uh.edu/partners/industry-advisory-board/maetzold) Under his leadership, Castle Biosciences achieved successful private financing rounds, a 2019 IPO, and acquisitions including the myPath® Melanoma test and Cernostics, Inc. in 2021.[[2]](https://txlifescienceforum.org/person/derek-maetzold) The company, headquartered in Friendswood, Texas, develops diagnostic and prognostic tests for dermatologic cancers and other high-need diseases.[[3]](https://www.zoominfo.com/p/Derek-Maetzold/331878065) Prior to Castle Biosciences—his first venture in molecular diagnostics—Maetzold spent 24 years in pharmaceutical development and commercialization, dividing time between multinational firms Sandoz (now Novartis), Schering (now Merck), and biotech companies Amylin (now BMS/AstraZeneca) and Encysive Pharmaceuticals (now Pfizer), focusing on business development, licensing, and commercial oversight of pre-approved therapies.[[1]](https://convention.bio.org/speaker/derek-maetzold)[[2]](https://txlifescienceforum.org/person/derek-maetzold)[[3]](https://www.zoominfo.com/p/Derek-Maetzold/331878065)[[4]](https://career.egr.uh.edu/partners/industry-advisory-board/maetzold) He holds a Bachelor of Science from George Mason University and has received prestigious awards, including a Gold Lifetime Achievement Award from the 2025 American Business Awards and CEO of the Year from The CEO Magazine.[[3]](https://www.zoominfo.com/p/Derek-Maetzold/331878065)[[5]](https://thedermdigest.com/for-the-win-castle-biosciences-ceo-derek-maetzold-receives-high-honor-from-the-american-business-awards/)[[6]](https://ir.castlebiosciences.com/news/news-details/2025/Castle-Biosciences-Founder-President-and-CEO-Derek-Maetzold-Honored-with-the-CEO-of-the-Year-Award-by-The-CEO-Magazine/default.aspx)

View full insider profile →

Trade Price

$25.55

Quantity

4,172

Total Value

$106,599.00

Shares Owned

275,593

Trade Date

Thursday, March 26, 2026

10 days ago

SEC Filing Date

Monday, March 30, 2026

Filed 4 days after trade

HEALTHCAREDIAGNOSTICS & RESEARCH

About Castle Biosciences Inc

Company Overview

No company information available
View news mentioning CSTL

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5228951

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime